The inflammatory response occurring in acute myocardial infarction (AMI) has been proposed as a potential pharmacological target. Sodium-glucose co-transporter 2 inhibitors (SGLT2-I) currently receive intense clinical interest in patients with and without diabetes mellitus (DM) for their pleiotropic beneficial effects. We tested the hypothesis that SGLT2-I have anti-inflammatory effects along with glucose-lowering properties. Therefore, we investigated the link between stress hyperglycemia, inflammatory burden, and infarct size in a cohort of type 2 diabetic patients presenting with AMI treated with SGLT2-I versus other oral anti-diabetic (OAD) agents.

Infarct size, inflammatory burden, and admission hyperglycemia in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: a multicenter international registry / Paolisso, Pasquale; Bergamaschi, Luca; Santulli, Gaetano; Gallinoro, Emanuele; Cesaro, Arturo; Gragnano, Felice; Sardu, Celestino; Mileva, Niya; Foà, Alberto; Armillotta, Matteo; Sansonetti, Angelo; Amicone, Sara; Impellizzeri, Andrea; Casella, Gianni; Mauro, Ciro; Vassilev, Dobrin; Marfella, Raffaele; Calabrò, Paolo; Barbato, Emanuele; Pizzi, Carmine. - In: CARDIOVASCULAR DIABETOLOGY. - ISSN 1475-2840. - 21:1(2022). [10.1186/s12933-022-01506-8]

Infarct size, inflammatory burden, and admission hyperglycemia in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: a multicenter international registry

Santulli, Gaetano
Formal Analysis
;
2022

Abstract

The inflammatory response occurring in acute myocardial infarction (AMI) has been proposed as a potential pharmacological target. Sodium-glucose co-transporter 2 inhibitors (SGLT2-I) currently receive intense clinical interest in patients with and without diabetes mellitus (DM) for their pleiotropic beneficial effects. We tested the hypothesis that SGLT2-I have anti-inflammatory effects along with glucose-lowering properties. Therefore, we investigated the link between stress hyperglycemia, inflammatory burden, and infarct size in a cohort of type 2 diabetic patients presenting with AMI treated with SGLT2-I versus other oral anti-diabetic (OAD) agents.
2022
Infarct size, inflammatory burden, and admission hyperglycemia in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: a multicenter international registry / Paolisso, Pasquale; Bergamaschi, Luca; Santulli, Gaetano; Gallinoro, Emanuele; Cesaro, Arturo; Gragnano, Felice; Sardu, Celestino; Mileva, Niya; Foà, Alberto; Armillotta, Matteo; Sansonetti, Angelo; Amicone, Sara; Impellizzeri, Andrea; Casella, Gianni; Mauro, Ciro; Vassilev, Dobrin; Marfella, Raffaele; Calabrò, Paolo; Barbato, Emanuele; Pizzi, Carmine. - In: CARDIOVASCULAR DIABETOLOGY. - ISSN 1475-2840. - 21:1(2022). [10.1186/s12933-022-01506-8]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/899938
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 75
  • ???jsp.display-item.citation.isi??? ND
social impact